U.S. Pharma Stock News

Wondering whether U-Haul Holding is a bargain or a value trap at around US$48.76? This breakdown will help you size up the stock with a clear valuation lens. The share price has moved 2.1% over the last 7 days, while returns sit at a 2.2% decline over 30 days and a 3.5% decline year to date, with a 16.9% decline over the past year and 19.9% and 20.4% declines across the 3 and 5 year periods respectively. Recent coverage has focused on U-Haul Holding as a long established name in do it...

Investors may be wondering whether Ituran Location and Control is still priced attractively after a strong run, or if most of the easy gains are already on the table. The stock last closed at US$51.48, with returns of 5.0% over 7 days, 3.9% over 30 days, 21.1% year to date, 74.1% over 1 year, 179.8% over 3 years and 192.4% over 5 years. This performance may have changed how investors are thinking about risk and reward. Recent company news has kept Ituran Location and Control in focus for...

Dorman Products (NasdaqGS:DORM) has appointed President and CEO Kevin Olsen as Chairman of the Board. Former Chairman Steven Berman will remain on the board following this leadership change. The move combines the CEO and Chairman roles, signaling a new governance structure for the company. Dorman Products, which focuses on replacement parts for the automotive aftermarket, now has Kevin Olsen serving as President, CEO and Chairman. For investors, this kind of leadership consolidation can...

Giftify’s CardCash will be integrated into Capital One Shopping, reaching tens of millions of users.

Regulatory milestone for lorundrostat Mineralys Therapeutics (MLYS) recently reported that the FDA accepted its New Drug Application for lorundrostat in hypertension, while also updating investors on the Explore OSA trial in obstructive sleep apnea. See our latest analysis for Mineralys Therapeutics. Mineralys Therapeutics’ share price has pulled back over the past quarter, with a 90 day share price return of 19.92% decline and year to date return of 20.72% decline. However, the 1 year total...

Artificial intelligence in healthcare is one of the clearest ways technology meets real world need, especially as higher energy prices, geopolitical tension, and sticky inflation keep pressure on costs and productivity. While many sectors face softer activity and rising input prices, AI tools that support better diagnostics, smoother hospital operations, and faster drug discovery speak directly to efficiency and outcomes. This screener focuses on companies applying AI to these problems,...

If you are trying to work out whether Credit Acceptance at around US$444 per share looks expensive or offers value, the starting point is understanding what the current share price actually reflects. Over the last week the stock is up 5.0%, while the 1 year return sits at a 5.0% decline and the year to date move is a 2.0% decline, which hints that sentiment around risk and reward has shifted more than once recently. The share price moves sit against a backdrop of ongoing attention on...

Why Virgin Galactic’s latest filings and results are drawing attention Virgin Galactic Holdings (SPCE) has come back into focus after its fourth quarter and full year 2025 results, alongside a new shelf registration for common stock tied to an employee stock ownership plan. The company reported fourth quarter 2025 sales of US$0.312 million and a net loss of US$62.72 million, with full year sales of US$1.54 million and a net loss of US$278.91 million, prompting fresh interest in its capital...

If you are wondering whether WESCO International's share price still offers value, or if the easier gains have already been made, this article breaks down what the current price might be implying. The stock most recently closed at US$278.57, with returns of 1.8% over 7 days, 5.5% over 30 days, 10.5% year to date, 111.4% over 1 year, 110.0% over 3 years, and 232.4% over 5 years. Recent market attention around WESCO International has focused on its role as a key distributor in capital goods...

If you are wondering whether Clearway Energy's share price still offers value after a strong run, the key is understanding what the current market price might already be factoring in. The stock last closed at US$39.64, with returns of 1.2% over 7 days, 12.7% over 30 days, 23.4% year to date, 68.3% over 1 year, 58.3% over 3 years and 94.3% over 5 years. This raises the question of how much of the story is already reflected in the valuation. Recent news around Clearway Energy has focused on...

In its latest results, WillScot Holdings reported a 13% year-over-year decline in EBITDA, a similar drop in units on rent, and wrote off about 15% of its rental fleet, underscoring mounting financial and operational pressure. These fleet impairments and signs of tougher competition, particularly from United Rentals, point to a business mix tilting toward smaller, less profitable segments. Against this backdrop of fleet write-offs and weakening core metrics, we will assess how the news...

Why Brookfield Wealth Solutions is on investors’ radar today Brookfield Wealth Solutions (BNT) has been drawing attention after a period where the share price shows mixed returns across different time frames. This has prompted closer scrutiny of its business mix and current valuation. See our latest analysis for Brookfield Wealth Solutions. The latest 1 day share price return of a 0.4% decline and 90 day share price return of a 12% decline contrast with a 1 year total shareholder return of...

Wondering whether Vera Therapeutics at around US$40.45 is still offering value, or if the easy gains are behind it? This article is designed to help you frame that question clearly. The stock has returned 6.2% over the last week and 3.5% over the last month, while year to date it is down 16.8% but up 102.8% over the past year and a very large amount over three years. This naturally raises questions about what is already priced in. Recent coverage has focused on Vera Therapeutics as investors...

Some AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders may be a little concerned to see that the Independent Director, John...

Check Point Software Technologies Ltd. ( NASDAQ:CHKP ) just reported some strong earnings, and the market reacted...

If you are wondering whether Louisiana-Pacific at around US$72 a share is offering good value or is already pricing in a lot of expectations, this article will help you frame that question using several valuation lenses. The stock has been choppy recently, with a 2.6% gain over the last 7 days, a 7.2% decline over 30 days, and year-to-date returns showing an 11.7% decline, while the 3-year and 5-year returns sit at 35.5% and 22.4% respectively. Recent attention on Louisiana-Pacific has...

If you are wondering whether QuidelOrtho's current share price reflects its underlying value, this article walks through the key numbers that investors tend to focus on before making a decision. QuidelOrtho last closed at US$15.88, with returns of 4.1% over the past week, a 23.8% decline over the past month, and year to date and 1 year returns of 44.8% and 44.0% declines respectively. The 3 year and 5 year returns sit at 82.5% and 87.5% declines. These moves come as investors reassess the...

The United States market has experienced a notable upswing, climbing 4.4% in the last week and an impressive 32% over the past year, with earnings projected to grow by 16% annually. In this environment, identifying stocks that may be undervalued requires a keen eye for potential growth and resilience amidst broader market gains, as highlighted by companies like BillionToOne and others.

The market has climbed 4.4% in the last 7 days and is up 32% over the last 12 months, reflecting strong investor confidence. For those looking to invest in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value when backed by solid financial foundations. This article highlights several penny stocks that demonstrate financial strength and potential for long-term growth amidst current market conditions.

The United States market has shown impressive momentum, with a 4.4% increase over the last week and a remarkable 32% gain over the past year, while earnings are projected to grow by 16% annually. In this dynamic environment, identifying small-cap stocks with strong potential can offer unique opportunities for investors seeking to capitalize on emerging growth stories within the market.

Nelnet, Inc. recently entered into a new Credit Agreement for a US$435 million unsecured line of credit maturing on March 31, 2031, while terminating its prior US$495 million facility that was due in 2026 and carried no outstanding balance at the time. This refreshed, long-dated borrowing capacity, backed by customary financial covenants and subsidiary guarantees, underscores the company’s emphasis on maintaining flexible funding for general corporate purposes. With this extended US$435...

Key performance context for PayPay PayPay (PAYP) has drawn attention after a 10.37% one day decline and an 8.81% drop over the past week, prompting investors to reassess its fundamentals and recent share price moves. The company reports annual revenue of ¥355,530 and net income of ¥111,208, with revenue growth of 16.82% and net income growth of 5.77% in the most recent year, all in its reporting currency. See our latest analysis for PayPay. The recent 10.37% one day share price return decline...

In recent months, the Pennsylvania Public Utility Commission held public hearings and suspended UGI Utilities’ proposed natural gas distribution rate increase, which sought an 8.05% rise in annual operating revenues and would have lifted typical residential bills by about 8–9% to fund infrastructure, cybersecurity, and IT upgrades. This regulatory pushback highlights how strongly public sentiment and oversight can influence UGI’s ability to recover investment spending through higher rates, a...

Immunovant (IMVT) is back in focus after reporting that two Phase 3 studies of batoclimab in thyroid eye disease did not meet their primary endpoint, prompting a shift in attention toward its IMVT-1402 program. See our latest analysis for Immunovant. Despite the batoclimab setback, Immunovant’s recent 1-day and 7-day share price returns of 1.59% and 5.69% suggest some near term optimism. Its 72.97% 1-year total shareholder return keeps the longer term story firmly in focus. If you are...